Navigation Links
Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results
Date:2/14/2008

ic nephropathy and we are

actively pursuing ways to monetize this asset.

-- Extended our research collaboration agreement with Bristol-Myers

Squibb Company to develop and commercialize novel therapies targeted

against the Liver X Receptor. We also received a milestone payment of

$5.0 million from Bristol-Myers Squibb as a result of the acceptance

of an IND, or foreign equivalent.

-- Submitted XL139 to Bristol-Myers Squibb Company in December 2007 under

our oncology collaboration agreement. In January 2008, Bristol-Myers

Squibb exercised its option to develop and commercialize XL139,

thereby triggering a $20.0 million selection milestone payment, and we

exercised our option to co-develop and co-commercialize the compound

in the United States and receive royalties on product sales outside of

the United States.

-- Received $18.0 million from the sale of a major portion of our plant

trait assets to Agrigenetics, Inc., a wholly-owned subsidiary of The

Dow Chemical Company.

-- Sold an 80.1% stake in Artemis to Taconic Farms, for $19.8 million.

Corporate Development

-- Completed a public offering of common stock, raising net proceeds of

$71.9 million.

-- Appointed Richard E. Buller, M.D., Ph.D. to the newly created position

of Vice President, Translational Medicine, Arthur DeCillis, M.D. to

the position of Vice President, Clinical Research, and Anne Champsaur,

M.D. to the position of Vice President, Drug Safety.

-- Appointed Jose Baselga, M.D., a leading expert in oncology drug

discovery, to our Scientific Advisory Board.

-- Appointed Carl B. Feldbaum, president emeritus of the Biotechnology

Industry Organization, to our Board of Directors.

"2007 was an exceptional year in the growth and development of Exelixis -- w
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Exelixis Announces February 14 Webcast of Its Fourth Quarter and Full Year 2007 Financial Results Conference Call
2. Exelixis Announces February 12 Webcast of Presentation at the 10th Annual BIO CEO and Investor Conference
3. Exelixis Announces January 31 Webcast of Presentation at the 2008 Wachovia Healthcare Conference
4. Exelixis Announces Senior Management Promotions
5. Exelixis Announces January 10 Webcast of Presentation at the 26th Annual JPMorgan Healthcare Conference
6. Exelixis Submits XL139 Diligence Report to Bristol-Myers Squibb
7. Reminder: Exelixis Announces December 5 Webcast of Its Third Annual R&D Day
8. Exelixis Announces November 28 Webcast of Presentation at the Lazard Capital Markets Fourth Annual Healthcare Conference
9. Exelixis Announces November 27 Webcast of Presentation at the 19th Annual Piper Jaffray Health Care Conference
10. Exelixis Announces December 5 Webcast of Its Third Annual R&D Day
11. Exelixis Sells 80% Stake in Artemis to Taconic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 30, 2015 HIGHLIGHTS:Q2 2015 Results ... , Reported sales were $697 million compared to ... grew organically by 8%, and changes in foreign currency ... sales by 1%. , By business unit, organic ... and 11% in SAFC Commercial. , Reported diluted ...
(Date:7/29/2015)... , July 30, 2015 ... la santé, publie ses résultats pour le premier ... commente les résultats. Visionner l,interview ... http://www.eurobusinessmedia.com/ceo-direct/sanofi/sanofi-h1-2015-results-interview-with-ceo-olivier-brandicourt?utm_source=ceo-direct&utm_medium=wire Au sommaire de ... - Moteurs de croissance - ...
(Date:7/29/2015)...  HealthSouth Corporation (NYSE: HLS ), one ... services, offering both facility-based and home-based post-acute services, ... second quarter ended June 30, 2015. ... growth in both segments and an 11.0% increase ... and Chief Executive Officer of HealthSouth. "While reported ...
(Date:7/29/2015)... , July 29, 2015  AmnioChor Inc., an ... technology, is very pleased to announce that the Musculoskeletal ... has agreed to invest in their seed round of ... placental tissue storage capabilities. AmnioChor,s technology ... and the human stem cells living within those tissues. ...
Breaking Biology Technology:Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 2Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 4Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 6Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 7Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 8Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 10Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 11Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 12Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 13Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 14Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 15Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 16Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 17Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 18Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 19Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 20HealthSouth Reports Results for Second Quarter 2015 2HealthSouth Reports Results for Second Quarter 2015 3HealthSouth Reports Results for Second Quarter 2015 4HealthSouth Reports Results for Second Quarter 2015 5HealthSouth Reports Results for Second Quarter 2015 6HealthSouth Reports Results for Second Quarter 2015 7HealthSouth Reports Results for Second Quarter 2015 8HealthSouth Reports Results for Second Quarter 2015 9HealthSouth Reports Results for Second Quarter 2015 10HealthSouth Reports Results for Second Quarter 2015 11HealthSouth Reports Results for Second Quarter 2015 12HealthSouth Reports Results for Second Quarter 2015 13HealthSouth Reports Results for Second Quarter 2015 14HealthSouth Reports Results for Second Quarter 2015 15HealthSouth Reports Results for Second Quarter 2015 16HealthSouth Reports Results for Second Quarter 2015 17
... PARIS, November 27 Stallergenes ... adults and children,through a Mutual Recognition Procedure. Germany, the ... Member state. , Oralair(R) is ... Estonia, France, Germany, Greece, Hungary, Ireland, Italy,Latvia, Lithuania, Luxembourg, ...
... ... ... Speak at Economic Club of Canada., , , , ,Who: ,David Appia, French Ambassador for ... biography of David Appia go to www.investinfrance.org . , , ,What: ,Ambassador Appia ...
... , SAN DIEGO, Nov. 25 Ardea Biosciences, ... Quart, Pharm.D., president and chief executive officer, will present at ... details are as follows:,Piper Jaffray 21st Annual Health Care Conference,Date: ... 2:00 p.m. Eastern Time,Location: The ...
Cached Biology Technology:STALLERGENES is Granted a Marketing Authorization for Oralair(R) in Europe 2STALLERGENES is Granted a Marketing Authorization for Oralair(R) in Europe 3French Ambassador for International Investment to Visit Toronto December 11 2Ardea Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference 2
(Date:6/30/2015)... , June 30, 2015 To bolster its ... provider HYPR Corp. announced today the addition of two new ... serve as board advisor and David Raviv will ... team underscore HYPR Corp.,s commitment to providing the most secure ... Dimitri Sirota co-founded Layer 7 Technologies, a provider of ...
(Date:6/29/2015)... DUBLIN , June 24, 2015 ... the addition of the "Latin America Biomedical Sensors ... to their offering. The Latin America Biomedical ... at a CAGR of 2.04% over the period 2014-2020 ... that are adaptable to the genetic formulation of each ...
(Date:6/25/2015)... , June 25, 2015 ... Sensors Market by Type (Swipe & Area), Technology, Material ... Government, Healthcare, Commercial Security & Others) & Geography ... by marketsandmarkets, the said market is expected to ... of 17.1%. Browse 76 market ...
Breaking Biology News(10 mins):HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3Latin America Biomedical Sensors Market Report 2015-2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4
... about the way water behaves inside carbon nanotubes could ... ultra-tiny high-tech devices to scientists, understanding of biological processes, ... at Chapel Hill. The findings, published in the ... , relate to a property of so-called "nano-confined" water ...
... communities often rely on friends to help get what they ... Currie at the University of Wisconsin-Madison, many microbes, plants and ... study, which was funded by the National Science Foundation (NSF) ... journal Science , describes the complex relationship between a ...
... The most comprehensive geological review ever undertaken of the upper ... and dammed rivers could flood large swaths of wetlands this ... "In terms of sea-level increases and river sediments flowing ... will face conditions they last saw in the Holocene, from ...
Cached Biology News:UNC study on properties of carbon nanotubes, water could have wide-ranging implications 2Beetles get by with a little help from their friends 2Bays on US Gulf Coast vulnerable to flooding 2
Sequencing and primer design rolled into one. Just give us your clone and a reference sequence, and we'll do the rest. Single-strand or double-strand coverage. Guaranteed results....
... to human XAB2 (amino terminus) XAB2 ... its interaction with XPA. Immunoprecipitation experiments have ... interacts with the transcription-coupled repair-specific proteins CSA ... polymerase II. Microinjection experiments with XAB2 antibodies ...
... using advanced automated high throughput microplate processing equipment that dispenses ... accommodate virtually any lot size of the following formats (with ... 8 and 12 well strips, ... 384 well microplate, 1536 ...
...
Biology Products: